MA56535A - Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées - Google Patents

Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Info

Publication number
MA56535A
MA56535A MA056535A MA56535A MA56535A MA 56535 A MA56535 A MA 56535A MA 056535 A MA056535 A MA 056535A MA 56535 A MA56535 A MA 56535A MA 56535 A MA56535 A MA 56535A
Authority
MA
Morocco
Prior art keywords
hbv
vaccines
hepatitis
virus
self
Prior art date
Application number
MA056535A
Other languages
English (en)
Inventor
Daniel Boden
Helen Horton
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56535A publication Critical patent/MA56535A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA056535A 2019-06-20 2020-06-19 Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées MA56535A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863961P 2019-06-20 2019-06-20
US202063006925P 2020-04-08 2020-04-08

Publications (1)

Publication Number Publication Date
MA56535A true MA56535A (fr) 2022-04-27

Family

ID=71833364

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056535A MA56535A (fr) 2019-06-20 2020-06-19 Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Country Status (7)

Country Link
US (1) US20220313815A1 (fr)
EP (1) EP3986458A1 (fr)
AU (1) AU2020298267A1 (fr)
CA (1) CA3143632A1 (fr)
MA (1) MA56535A (fr)
TW (2) TWI828168B (fr)
WO (1) WO2020255055A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
CN116171150A (zh) 2020-08-14 2023-05-26 阿克丘勒斯治疗公司 冻干脂质纳米颗粒的方法
BR112024001911A2 (pt) * 2021-07-30 2024-04-30 Arcturus Therapeutics Inc Vacinas de rna
CN115960922A (zh) * 2021-10-09 2023-04-14 吴可行 自复制rna分子设计及其应用
US12115217B2 (en) 2022-11-18 2024-10-15 Trustees Of Boston University Self-replicating RNA and uses thereof
AU2024328030A1 (en) * 2023-08-24 2026-03-12 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
WO2025088152A1 (fr) 2023-10-27 2025-05-01 Ziphius Nv 5'utr modifiées

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
EP3508219A1 (fr) 2011-07-06 2019-07-10 GlaxoSmithKline Biologicals S.A. Vaccins arn autoréplicatives prime - protein boost
TWI575070B (zh) * 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
KR102535764B1 (ko) 2016-03-28 2023-05-30 아이커 메디칼 시스템스 인코포레이티드 치료제를 전달하기 위한 장치
EP3526332B1 (fr) * 2016-10-17 2024-06-26 Janssen Pharmaceuticals, Inc. Système réplicon recombinant de virus et leurs utilisations
CA3045650A1 (fr) * 2016-12-05 2018-06-14 Janssen Pharmaceuticals, Inc. Compositions et methodes d'activation d'expression genique
GB201705765D0 (en) * 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd HBV vaccine
CA3085492A1 (fr) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methodes et appareil pour l'administration de vaccins contre le virus de l'hepatite b (vhb)
MX2020006471A (es) * 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
ES2963179T3 (es) * 2017-12-19 2024-03-25 Janssen Sciences Ireland Unlimited Co Vacunas contra el virus de la hepatitis b (VHB) y usos de las mismas
US12331076B2 (en) * 2018-10-08 2025-06-17 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics

Also Published As

Publication number Publication date
TW202108598A (zh) 2021-03-01
WO2020255055A1 (fr) 2020-12-24
US20220313815A1 (en) 2022-10-06
EP3986458A1 (fr) 2022-04-27
TWI769467B (zh) 2022-07-01
AU2020298267A1 (en) 2022-02-17
TWI828168B (zh) 2024-01-01
CA3143632A1 (fr) 2020-12-24
TW202235428A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
MA56535A (fr) Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA51311A (fr) Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
MA50520A (fr) Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA50524A (fr) Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb)
MA55321A (fr) Vaccins à base d'arn contre le vih
Wang et al. CRISPR-Cas based antiviral strategies against HIV-1
Killip et al. Influenza virus activation of the interferon system
EP4234691A3 (fr) Méganucléases génétiquement modifiées spécifiques pour des séquences de reconnaissance dans le génome du virus de l'hépatite b
MA56534A (fr) Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
EP3325097A4 (fr) Compositions et agents contre le virus de l'hépatite b et utilisations de ceux-ci
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
IL285257A (en) RNAi materials for hepatitis b virus infection
WO2011015656A3 (fr) Composition pour le traitement d'une infection par le virus de l'hépatite b
WO2008099189A3 (fr) Virus de l'herpès simplex et procédés de réplication virale
IL288019A (en) Preparations and methods for treating hepatitis b virus infection
MA51312A (fr) Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
EP4022086C0 (fr) Compositions et procédés pour l'amplification et la détection de l'arn du virus de l'hépatite b, comprenant l'arn du vhb transcrit à partir de adnccc
IL292625B1 (en) Viruses with adapted capsid proteins
IL275429A (en) Methods and device for administering hepatitis virus HBV vaccines) B)
PH12023550030A1 (en) Rna replicon vaccines against hbv
MA56524A (fr) Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
EP2351843A3 (fr) Systemes de vecteurs rabiques, compositions et procedes correspondants
DK4069729T3 (da) Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
EP2484376A4 (fr) Méthode, trousse, plasmide et composition pour induire une réponse immunitaire contre le virus de la dengue, au moyen de vaccins à adn et de virus chimériques
HRP20090230T1 (hr) Replikacijski-defektni rna virusi kao cjepiva